<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83231">
  <stage>Registered</stage>
  <submitdate>9/10/2008</submitdate>
  <approvaldate>6/02/2009</approvaldate>
  <actrnumber>ACTRN12609000085279</actrnumber>
  <trial_identification>
    <studytitle>A double-blind, randomised study on the effects of STW 5 on symptoms and immunologic function in patients with irritable bowel syndrome</studytitle>
    <scientifictitle>A double-blind, randomised study on the effects of STW 5 on symptoms and immunologic function in patients with irritable bowel syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Irritable Bowel Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a cross over study examining the effects of a herbal preperation, Iberogast (STW 5) and placebo for patients suffering from Irritable Bowel Syndrome compared to healthy controls. Iberogast is a liquid consisting of 9 plant extracts. Each treatment arm is conducted over 2 weeks. Study medication is administered at 20 drops 3 times per day, orally. With a washout period of 1 week between treatment arms.</interventions>
    <comparator>cross over design: healthy volunteers and Iriitable Bowel Syndrome (IBS) subjects will receive 2 weeks of herbal preparation and 2 weeks of placebo. The placebo has been prepared to taste similar to Iberogast. Placebo liquid is  taken orally, 20 drops 3 times a day for the duration of 2 weeks. The Placebo consists of ethanol 28-34% (v/v),herbal flavour and liquorice flavour. A Washout period of one week between treatments.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the improvement of symptoms in patients with IBS during treatment with the herbal preparation, Iberogast (STW 5) and placebo the subject will complete previously standardised questionnaires</outcome>
      <timepoint>Visit 1 baseline,  visit 2 week 2, visit 3 week 4, visit 4 week 5, visit 5 week 7.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Through analysis subjects blood sample at visit 1,3,4 and 5 we will measure the influence of the treatment on Peripheral Blood Monouclear cell (PBMC)-mediated cytokine secretion and gut homing T cells.</outcome>
      <timepoint>Visit 1 baseline, visit 3 week 4, visit 4 week 5, visit 5 week 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Symptoms consitent with IBS according to the Rome III criteria; Not recieved antibiotics 8 wks prior; Not taking immunosuppressive medications;No Laxatives, no prokinetic drugs for 2 weeks;
Able to sign consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Previous abdominal or gynaecological surgery (except appendectomies and cholecystectomies) previous gastrointestinal cancer;Known peptic ulcers;pregnancy or breastfeeding;chronic inflammatory disease, cardiovascular disease; respiratory disease;Diabetes mellitus; Epilepsy;</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital Gastroenterology and Hepatology</primarysponsorname>
    <primarysponsoraddress>Ward Q7
North Terrace
Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>STEIGERWALD Arzneimittelwerk GmbH</fundingname>
      <fundingaddress>Havelstr. 5, D-64295 Darmstadt

Adelaide SA 5000</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Adelaide Hospital Gastroenterology &amp; Hepatology Unit</fundingname>
      <fundingaddress>Ward Q7
North Terrace
Adelaide SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Department of Health (DoH)</sponsorname>
      <sponsoraddress>Level 13, 11 Waymouth Str, Adelaide SA 5000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed to provide information about the way the gastroinstestinal tract responds to the treatment of herbal medication Iberogast.We seek to determine the effects of Iberogast on symptoms and stool frequencey as well as immunologic function.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jane Andrews</name>
      <address>Gastroenterolgy Unit Ward Q7
Royal Adelaide Hospital 
North Terrace
Adelaide SA 5000</address>
      <phone>088222 5207</phone>
      <fax />
      <email>jane.andrews@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jane Andrews</name>
      <address>Gastroenterolgy Unit Ward Q7
Royal Adelaide Hospital 
North Terrace
Adelaide SA 5000</address>
      <phone>088222 5207</phone>
      <fax />
      <email>jane.andrews@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>